Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers

Abstract

Background

A recent phase II clinical trial (Reducing Residual Albuminuria in Subjects with Diabetes and Nephropathy with AtRasentan trial and an identical trial in Japan (RADAR/JAPAN)) showed that the endothelin A receptor antagonist atrasentan lowers albuminuria, blood pressure, cholesterol, hemoglobin, and increases body weight in patients with type 2 diabetes and nephropathy. We previously developed an algorithm, the Parameter Response Efficacy (PRE) score, which translates short-term drug effects into predictions of long-term effects on clinical outcomes.

Design

We used the PRE score on data from the RADAR/JAPAN study to predict the effect of atrasentan on renal and heart failure outcomes.

Methods

We performed a post-hoc analysis of the RADAR/JAPAN randomized clinical trials in which 211 patients with type-2 diabetes and nephropathy were randomly assigned to atrasentan 0.75 mg/day, 1.25 mg/day, or placebo. A PRE score was developed in a background set of completed clinical trials using multivariate Cox models. The score was applied to baseline and week-12 risk marker levels of RADAR/JAPAN participants, to predict atrasentan effects on clinical outcomes. Outcomes were defined as doubling serum creatinine or end-stage renal disease and hospitalization for heart failure.

Results

The PRE score predicted renal risk changes of −23% and −30% for atrasentan 0.75 and 1.25 mg/day, respectively. PRE scores also predicted a small non-significant increase in heart failure risk for atrasentan 0.75 and 1.25 mg/day (+2% vs. +7%). Selecting patients with >30% albuminuria reduction from baseline (responders) improved renal outcome to almost 50% risk reduction, whereas non-responders showed no renal benefit.

Conclusions

Based on the RADAR/JAPAN study, with short-term changes in risk markers, atrasentan is expected to decrease renal risk without increased risk of heart failure. Within this population albuminuria responders appear to contribute to the predicted improvements, whereas non-responders showed no benefit. The ongoing hard outcome trial (SONAR) in type 2 diabetic patients with >30% albuminuria reduction to atrasentan will allow us to assess the validity of these predictions.

Keywords

Type 2 diabetes renal disease cardiovascular disease albuminuria atrasentan

Get full access to this article

View all access options for this article.

References

Gregg

Wang

. Changes in diabetes-related complications in the United States, 1990–2010. N Engl J Med 2014; 370: 1514–1523.

Heerspink

de Zeeuw

. The kidney in type II diabetes therapy. Rev Diabet Stud 2011; 8: 392–402.

Kohan

Pollock

. Endothelin antagonists for diabetic and non-diabetic chronic kidney disease. Br J Clin Pharmacol 2013; 76: 573–579.

Kohan

Pritchett

Molitch

. Addition of atrasentan to renin–angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol 2011; 22: 763–772.

Kohan

Barton

. Endothelin and endothelin antagonists in chronic kidney disease. Kidney Int 2014; 8: 896–904.

Chandrashekar

Juncos

. Endothelin antagonists in diabetic nephropathy: Back to basics. J Am Soc Nephrol 2014; 25: 869–871.

Wenzel

Littke

Kuranoff

. for the SPP301 (Avosentan) Endothelin Antagonist Evaluation in Diabetic Nephropathy Study investigators. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol 2009; 20: 655–664.

Weber

Black

Bakris

. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: A randomised, double-blind, placebo-controlled trial. Lancet 2009; 374: 1423–1431.

Dhaun

Melville

Blackwell

. Endothelin-A receptor antagonism modifies cardiovascular risk factors in CKD. J Am Soc Nephrol 2013; 24: 31–36.

10.

de Zeeuw

Coll

Andress

. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J Am Soc Nephrol 2014; 25: 1083–1093.

11.

Mann

JFE

Green

Jamerson

. for the ASCEND Study Group. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 2010; 21: 527–535.

12.

Kalra

Moon

JCC

Coats

AJS

. Do results of the ENABLE (endothelin antagonist bosentan for lowering cardiac events in heart failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol 2002; 85: 195–197.

13.

Smink

Hoekman

Grobbee

. A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers. Eur J Prev Cardiol 2013; 21: 434–441.

14.

Smink

Miao

Eijkemans

MJC

. The importance of short-term off-target effects in estimating the long-term renal and cardiovascular protection of angiotensin receptor blockers. Clin Pharmacol Ther 2014; 95: 208–215.

15.

Heerspink

HJL

Grobbee

de Zeeuw

. A novel approach for establishing cardiovascular drug efficacy. Nat Rev Drug Discov 2014; 13: 942–942.

16.

Lambers Heerspink

Gansevoort

Brenner

. Comparison of different measures of urinary protein excretion for prediction of renal events. Journal of the American Society of Nephrology 2010; 21(8): 1355–1360.

17.

Hoekman

Lambers Heerspink

Viberti

. Predictors of congestive heart failure after treatment with an endothelin receptor antagonist. Clinical Journal of the American Society of Nephrology 2014; 9(3): 490–498.

18.

Heerspink

de Zeeuw

. Pharmacology: Defining the optimal dose of a new drug: A crucial decision. Nat Rev Nephrol 2009; 5: 498–500.

19.

Temple

. Enrichment of clinical study populations. Clin Pharmacol Ther 2010; 88: 774–778.

20.

Schievink B, de Zeeuw D, Parving H-H, et al. The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers. Br J Clin Pharmacol. Epub ahead of print 14 April 2015. DOI: 10.1111/bcp.12655.

21.

Moons

Kengne

Grobbee

. Risk prediction models: II. External validation, model updating, and impact assessment. Heart 2012; 98: 691–698.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.38 MB

0.14 MB

0.01 MB